The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl] pyridine (MTEP) in rodent models of anxiety

Neuropsychopharmacology

Volumn 29, Issue 11, 2004, Pages 1971-1979

  Busse, Chris S ^a   Brodkin, Jesse ^a   Tattersall, David ^a   Andersen, Jeffery J ^a   Warren, Noelle ^a   Tehrani, Lida ^a   Bristow, Linda J ^a   Varney, Mark A ^a   Cosford, Nicholas D P ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Anxiety; Metabotropic glutamate receptor 5; MTEP; Tolerance

Indexed keywords

3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; ALCOHOL; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; DIAZEPAM; GLUTAMATE RECEPTOR 5; GLUTAMATE RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL MODEL; ANXIETY; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ELECTRIC SHOCK; MALE; MOOD DISORDER; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RAT; RECEPTOR OCCUPANCY; STARTLE REFLEX; TRANQUILIZING ACTIVITY;

ANIMALS; ANXIETY; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, METABOTROPIC GLUTAMATE; THIAZOLES;

EID: 3042685523     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300540     Document Type: Article

References (42)

1. 3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine). Eur J Pharmacol 473: 35-40.
2. 3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl] pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: in vitro and in vivo characterization. J Pharmacol Exp Ther 303: 1044-1051.
3. Argyropoulos SP, Sandford JJ, Nutt DJ (2000). The psychobiology of anxiolytic drugs. Part 2. Pharmacological treatments of anxiety. Pharmacol Ther 88: 213-227.
4. Baude A, Nusser Z, Roberts JD, Mulvihill E, McIlhinney RA, Somogyi P (1993). The metabotropic glutamate receptor (mGluR1 alpha) is concentrated at perisynaptic membrane of neuronal subpopulations as detected by immunogold reaction. Neuron 11: 771-787.
5. Breysse N, Baunez C, Spooren W, Gasparini F, Amalric M (2002). Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J Neurosci 22: 5669-5678.
6. Brodkin J, Bradbury M, Busse C, Warren N, Bristow LJ, Varney MA (2002b). Reduced stress-induced hyperthermia in mGluR5 knockout mice. Eur J Neurosci 16: 2241-2244.
7. Brodkin J, Busse C, Sukoff SJ, Varney MA (2002a). Anxiolytic-like activity of the mGluR5 antagonist MPEP: a comparison with diazepam and buspirone. Pharmacol Biochem Behav 73: 359-366.
8. Cervo L, Munoz C, Bertaglia A, Samanin R (2000). Alnespirone and buspirone have anxiolytic-like effects in a conflict procedure in rats by stimulating 5-HT(1A) receptors. Behav Pharmacol 11: 153-160.
9. Conn PJ, Pin JP (1997). Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37: 205-237.
10. 3H]-methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor. Bioorg Med Chem Lett 13: 351-354.
11. Cosford ND, Tehrani L, Roppe J, Schweiger E, Smith ND, Anderson J et al (2003b). 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J Med Chem 46: 204-206.
12. Davidson JRT, DuPont RL, Hedges D, Haskins JT (1999). Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 60: 528-535.
13. Davis M (1979). Diazepam and flurazepam: effects on conditioned fear as measured with the potentiated startle paradigm. Psychopharmacology 62: 1-7.
14. Davis M, Falls WA, Campeau S, Kim M (1993). Fear-potentiated startle: a neural and pharmacological analysis. Behav Brain Res 58: 175-198.
15. DuPont RL, Rice DP, Miller LS, Shiraki SS, Rowland CR, Harwood HJ (1996). Economic costs of anxiety disorders. Anxiety 2: 167-172.
16. Gasparini F, Lingenhohl K, Stoehr N, Flor PJ, Heinrich M, Vranesic I et al (1999). 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective systemically active mGluR5 receptor antagonist. Neuropharmacology 38: 1493-1503.
17. Hascoët M, Bourin M (1997). Anitconflict effect of alpidem as compared with the benzodiazepine alprazolam in rats. Pharmacol Biochem Behav 56: 317-324.
18. Hu WY, Reiffenstein RJ, Wong L (1987). Interaction between flurazepam and ethanol. Alcohol Drug Res 7: 107-117.
19. Ikeda SR, Lovinger DM, McCool BA, Lewis DL (1995). Heterologous expression of metabotropic glutamate receptors in adult rat sympathetic neurons: subtype-specific coupling to ion channels. Neuron 14: 1029-1038.
20. Levy M, Jing J, Chikvashvili D, Thornhill WB, Lotan I (1998). Activation of a metabotropic glutamate receptor and protein kinase C reduce the extent of inactivation of the K+ channel Kv1.1/Kvbeta1.1 via dephosphorylation of Kv1.1. J Biol Chem 273: 6495-6502.
21. Lydiard RB (2000). An overview of generalized anxiety disorder: disease state-appropriate therapy. Clin Ther 22: A3-A19.
22. Lydiard RB, Brawman-Mintzer O, Ballenger JC (1996). Recent developments in the psychopharmacology of anxiety disorders. J Consult Clin Psychol 64: 660-668.
23. Maickel RP, Nash Jr JF (1986). Drug interactions with ethanol. Effects on body temperature and motor impairment. Neuropharmacology 25: 315-322.
24. Mathiesen JM, Svendsen N, Brauner-Osborne H, Thomsen C, Ramirez MT (2003). Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP. Br J Pharmacol 138: 1026-1030.
25. McCool BA, Pin JP, Harpold MM, Brust PF, Stauderman KA, Lovinger DM (1998). Rat group I metabotropic glutamate receptors inhibit neuronal Ca2+ channels via multiple signal transduction pathways in HEK 293 cells. J Neurophysiol 79: 379-391.
26. Petralia RS, Wang YX, Niedzielski AS, Wenthold RJ (1996). The metabotropic glutamate receptors, mGluR2 and mGluR3, show unique postsynaptic, presynaptic and glial localizations. Neuroscience 71: 949-976.
27. Pilc A, Kłodziñska A, Branski P, Nowak G, Pałucha A, Szewczyk B et al (2002). Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats. Neuropharmacology 43: 181-187.
28. Rakel RE (1990). Long-term buspirone therapy for chronic anxiety: a multicenter international study to determine safety. South Med J 83: 194-198.
29. Romano C, Sesma MA, McDonald CT, O'Malley K, Van den Pol AN, Olney JW (1995). Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J Comp Neurol 355: 455-469.
30. Roppe J, Smith ND, Huang D, Tehrani L, Wang B, Anderson J et al (in press). The discovery of novel heteroaryl azoles that are metabotropic glutamate subtype 5 (mGlu5) receptor antagonists with anxiolytic activity. J Med Chem.
31. Schulz B, Fendt M, Gasparini F, Lingenhöhl K, Kuhn R, Koch M (2001). The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl)- pyridine (MPEP) blocks fear conditioning in rats. Neuropharmacology 41: 1-7.
32. Shader RI, Greenblatt DJ (1993). Use of benzodiazepines in anxiety disorders. N Engl J Med 328: 1398-1405.
33. Shigemoto R, Kinoshita A, Wada E, Nomura S, Ohishi H, Takada M et al (1997). Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. J Neurosci 17: 7503-7522.
34. Shigemoto R, Nomura S, Ohishi H, Sugihara H, Nakanishi S, Mizuno N (1993). Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain. Neurosci Lett 163: 53-57.
35. Spooren WPJM, Schoeffter P, Gasparini F, Kuhn R, Gentsch C (2002). Pharmacological and endocrinological characterisation of stress-induced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY314582, MPEP and NKP608). Eur J Pharmacol 435: 161-170.
36. Spooren WPJM, Vassout A, Neijt HC, Kuhn R, Gasparini F, Roux S et al (2000). Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J Pharmacol Exp Ther 295: 1267-1275.
37. Takahashi T, Forsythe ID, Tsujimoto T, Barnes-Davies M, Onodera K (1996). Presynaptic calcium current modulation by a metabotropic glutamate receptor. Science 274: 594-597.
38. Tatarczynska E, Klodzinska A, Chojnacka-Wojcik E, Palucha A, Gasparini F, Kuhn R et al (2001). Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol 132: 1423-1430.
39. Varney MA, Cosford NDP, Jachec C, Rao SP, Sacaan A, Lin F-F et al (1999). SIB-1757 and SIB-1893: selective, non-competitive antagonists of metabotropic glutamate receptor type 5 (mGluR5). J Pharmacol Exp Ther 290: 170-181.
40. Volke V, Soosaar A, Kõks S, Vasar E, Männistö PT (1998). L-Argininine abolishes the anxiolytic-like effect of diazepam in the elevated plus maze in rats. Eur J Pharmacol 351: 287-290.
41. Yasumatsu H, Morimoto Y, Yamamoto Y, Takehara S, Fukuda T, Nakao T et al (1994). The pharmacological properties of Y23684, a benzodiazepine receptor partial agonist. Br J Pharmacol 111: 1170-1180.
42. Zhou FM, Hablitz JJ (1997). Metabotropic glutamate receptor enhancement of spontaneous IPSCs in neocortical interneurons. J Neurophysiol 78: 2287-2295.